Literature DB >> 6293975

Hematogenous Candida vertebral osteomyelitis treated with ketoconazole.

B A Dijkmans, M I Koolen, R P Mouton, T H Falke, P J van den Broek, J W van der Meer.   

Abstract

Candida vertebral osteomyelitis was diagnosed in a patient with systemic lupus erythematodes following X-ray evidence of osteomyelitis and the repeated culturing of Candida albicans from material obtained by needle biopsies from the third lumbar vertebra. The patient had been on glucocorticosteroids and parenteral nutrition six months previously. At that time, a yeast was cultured from the blood and the tip of the subclavian catheter which had been removed. After candida vertebral osteomyelitis was diagnosed, she was treated with ketoconazole for seven months. Recovery was impressive, as judged by the clinical and radiographic findings. At the time of writing this paper--12 months after the withdrawal of ketoconazole--the patient showed no signs of recurrence.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6293975     DOI: 10.1007/bf01640877

Source DB:  PubMed          Journal:  Infection        ISSN: 0300-8126            Impact factor:   3.553


  17 in total

1.  Hematogenous candida osteomyelitis. Report of three cases and review of the literature.

Authors:  J E Edwards; S B Turkel; H A Elder; R W Rand; L B Guze
Journal:  Am J Med       Date:  1975-07       Impact factor: 4.965

2.  Miconazole, a broad-spectrum antimycotic agent with antibacterial activity.

Authors:  J M Van Cutsem; D Thienpont
Journal:  Chemotherapy       Date:  1972       Impact factor: 2.544

Review 3.  Opportunistic mycotic osteomyelitis: bone infections due to Aspergillus and Candida species.

Authors:  M B Simpson; W G Merz; J P Kurlinski; M H Solomon
Journal:  Medicine (Baltimore)       Date:  1977-11       Impact factor: 1.889

4.  The activity of ketoconazole in clinical isolates of candida albicans cultured in a mycelium promoting medium.

Authors:  J Van Cutsem; M Borgers; M De Brabander
Journal:  Mykosen       Date:  1981-10

5.  The influence of gastric acidity on the bio-availability of ketoconazole.

Authors:  J W Van Der Meer; J J Keuning; H W Scheijgrond; J Heykants; J Van Cutsem; J Brugmans
Journal:  J Antimicrob Chemother       Date:  1980-07       Impact factor: 5.790

6.  Miconazole in cryptococcosis and systemic candidiasis: a word of caution.

Authors:  J E Bennett; J S Remington
Journal:  Ann Intern Med       Date:  1981-05       Impact factor: 25.391

7.  Osteomyelitis in heroin addicts.

Authors:  R S Holzman; F Bishko
Journal:  Ann Intern Med       Date:  1971-11       Impact factor: 25.391

8.  Antimycotic imidazoles. part 4. Synthesis and antifungal activity of ketoconazole, a new potent orally active broad-spectrum antifungal agent.

Authors:  J Heeres; L J Backx; J H Mostmans; J Van Cutsem
Journal:  J Med Chem       Date:  1979-08       Impact factor: 7.446

Review 9.  Severe candidal infections: clinical perspective, immune defense mechanisms, and current concepts of therapy.

Authors:  J E Edwards; R I Lehrer; E R Stiehm; T J Fischer; L S Young
Journal:  Ann Intern Med       Date:  1978-07       Impact factor: 25.391

10.  Suppression of cryptococcosis and histoplasmosis by ketoconazole in athymic nude mice.

Authors:  D M Williams; J R Graybill; D J Drutz; H B Levine
Journal:  J Infect Dis       Date:  1980-01       Impact factor: 5.226

View more
  3 in total

1.  Case report 762. Torulopsis glabrata spondylodiscitis as a late complication of an infected abdominal aortic graft.

Authors:  J Bogaert; L Lateur; A L Baert
Journal:  Skeletal Radiol       Date:  1992       Impact factor: 2.199

2.  Candida parapsilosis spondylodiscitis after lumbar discectomy.

Authors:  Kyungil Cho; Sun-Ho Lee; Eun-Sang Kim; Whan Eoh
Journal:  J Korean Neurosurg Soc       Date:  2010-04-30

3.  Candida osteomyelitis: analysis of 207 pediatric and adult cases (1970-2011).

Authors:  Maria N Gamaletsou; Dimitrios P Kontoyiannis; Nikolaos V Sipsas; Brad Moriyama; Elizabeth Alexander; Emmanuel Roilides; Barry Brause; Thomas J Walsh
Journal:  Clin Infect Dis       Date:  2012-08-21       Impact factor: 9.079

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.